Aeglea BioTherapeutics Company Profile (NASDAQ:AGLE)

About Aeglea BioTherapeutics (NASDAQ:AGLE)

Aeglea BioTherapeutics logoAeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGLE
  • CUSIP: N/A
  • Web: www.aegleabio.com
Capitalization:
  • Market Cap: $48.29 million
  • Outstanding Shares: 13,452,000
Average Prices:
  • 50 Day Moving Avg: $3.67
  • 200 Day Moving Avg: $5.39
  • 52 Week Range: $3.28 - $10.34
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.53
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.75 million
  • Price / Sales: 10.17
  • Book Value: $4.25 per share
  • Price / Book: 0.84
Profitability:
  • EBIDTA: ($23,540,000.00)
  • Net Margins: -492.49%
  • Return on Equity: -35.69%
  • Return on Assets: -33.71%
Debt:
  • Current Ratio: 15.27%
  • Quick Ratio: 15.27%
Misc:
  • Average Volume: 58,298 shs.
  • Beta: 4.08
  • Short Ratio: 0.97
 
Frequently Asked Questions for Aeglea BioTherapeutics (NASDAQ:AGLE)

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) posted its earnings results on Tuesday, May, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.47). The company earned $0.98 million during the quarter. Aeglea BioTherapeutics had a negative net margin of 492.49% and a negative return on equity of 35.69%. View Aeglea BioTherapeutics' Earnings History.

When will Aeglea BioTherapeutics make its next earnings announcement?

Aeglea BioTherapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Aeglea BioTherapeutics.

Where is Aeglea BioTherapeutics' stock going? Where will Aeglea BioTherapeutics' stock price be in 2017?

1 brokerages have issued twelve-month price targets for Aeglea BioTherapeutics' shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Aeglea BioTherapeutics' stock price to reach $19.00 in the next year. View Analyst Ratings for Aeglea BioTherapeutics.

Who are some of Aeglea BioTherapeutics' key competitors?

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the folowing people:

  • Armen B. Shanafelt Ph.D., Independent Chairman of the Board
  • David G. Lowe Ph.D., Co-Founder, President, Chief Executive Officer, Director
  • George Georgiou Ph.D., Co-Founder, Director
  • Charles N. York II, Chief Financial Officer, Vice President
  • Henry L. Hebel, Vice President - Product Development
  • Scott W. Rowlinson, Vice President - Research
  • Joseph E. Tyler, Vice President - Manufacturing
  • Suzanne Bruhn, Director
  • Russell J. Cox, Independent Director
  • Sandesh Mahatme, Independent Director

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

How do I buy Aeglea BioTherapeutics stock?

Shares of Aeglea BioTherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeglea BioTherapeutics' stock price today?

One share of Aeglea BioTherapeutics stock can currently be purchased for approximately $3.59.


MarketBeat Community Rating for Aeglea BioTherapeutics (NASDAQ AGLE)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about Aeglea BioTherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aeglea BioTherapeutics (NASDAQ:AGLE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (429.25% upside)

Analysts' Ratings History for Aeglea BioTherapeutics (NASDAQ:AGLE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2016BMO Capital MarketsReiterated RatingBuy$19.00N/AView Rating Details
5/9/2016Needham & Company LLCInitiated CoverageBuy$18.00N/AView Rating Details
5/2/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Aeglea BioTherapeutics (NASDAQ:AGLE)
Earnings by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)
Earnings History by Quarter for Aeglea BioTherapeutics (NASDAQ AGLE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($0.44)N/AView Earnings Details
5/9/20173/31/2017($0.47)($0.47)$0.98 millionViewN/AView Earnings Details
11/9/20169/30/2016($0.54)($0.47)$1.15 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.43)($0.46)$1.37 millionViewN/AView Earnings Details
5/19/2016Q1 2016($0.42)($7.10)$0.86 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aeglea BioTherapeutics (NASDAQ:AGLE)
Current Year EPS Consensus Estimate: $-2.03 EPS
Next Year EPS Consensus Estimate: $-2.34 EPS

Dividends

Dividend History for Aeglea BioTherapeutics (NASDAQ:AGLE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aeglea BioTherapeutics (NASDAQ:AGLE)
Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 31.44%
Insider Trades by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)
Institutional Ownership by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)
Insider Trades by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2017Orbimed Advisors LlcMajor ShareholderBuy109,300$5.16$563,988.00View SEC Filing  
4/12/2016Anthony QuinnDirectorBuy10,000$10.00$100,000.00View SEC Filing  
4/12/2016Bioventures Ltd NovartisMajor ShareholderBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aeglea BioTherapeutics (NASDAQ:AGLE)
Latest Headlines for Aeglea BioTherapeutics (NASDAQ:AGLE)
Source:
DateHeadline
bizjournals.com logoAustin biotech company loses CEO as disease treatments work through regulatory process
www.bizjournals.com - July 21 at 10:12 PM
finance.yahoo.com logoAeglea BioTherapeutics Announces Leadership Change
finance.yahoo.com - July 20 at 4:33 PM
finance.yahoo.com logoAeglea Bio shares down 2% after CEO resigns
finance.yahoo.com - July 20 at 4:33 PM
finance.yahoo.com logoAeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
finance.yahoo.com - July 10 at 8:21 PM
americanbankingnews.com logoValuEngine Lowers Aeglea BioTherapeutics, Inc. (AGLE) to Strong Sell
www.americanbankingnews.com - July 9 at 12:40 AM
americanbankingnews.com logo-$0.59 EPS Expected for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) This Quarter
www.americanbankingnews.com - July 4 at 8:10 PM
americanbankingnews.com logoAeglea BioTherapeutics, Inc. (AGLE) Lifted to Sell at ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM
americanbankingnews.com logo-$0.59 Earnings Per Share Expected for Aeglea Bio Therapeutics Inc (AGLE) This Quarter
www.americanbankingnews.com - June 8 at 8:40 PM
streetinsider.com logoAeglea BioTherapeutics (AGLE) Prices 3M Share Offering at $4.10/Sh
www.streetinsider.com - June 8 at 1:00 AM
finance.yahoo.com logoAeglea BioTherapeutics Prices Public Offering of Common Stock
finance.yahoo.com - June 6 at 10:32 AM
finance.yahoo.com logoAeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 5 at 6:36 PM
americanbankingnews.com logoAeglea Bio Therapeutics Inc (AGLE) Downgraded by TheStreet to D+
www.americanbankingnews.com - June 1 at 2:22 PM
finance.yahoo.com logoBristol-Myers' Opdivo Gets Priority Review for Liver Cancer
finance.yahoo.com - May 25 at 3:45 PM
finance.yahoo.com logoAchaogen's Plazomicin Gets Breakthrough Therapy Designation
finance.yahoo.com - May 24 at 3:24 PM
finance.yahoo.com logoAeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
finance.yahoo.com - May 23 at 3:27 PM
americanbankingnews.com logo Brokerages Expect Aeglea Bio Therapeutics Inc (AGLE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - May 12 at 4:02 PM
finance.yahoo.com logoETFs with exposure to Aeglea Biotherapeutics, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:41 PM
americanbankingnews.com logoAeglea Bio Therapeutics Inc (AGLE) Issues Earnings Results
www.americanbankingnews.com - May 10 at 9:14 PM
finance.yahoo.com logoAeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:30 PM
marketbeat.com logoAeglea reports 1Q loss
marketbeat.com - May 9 at 9:41 AM
finance.yahoo.com logoAeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 9:25 AM
finance.yahoo.com logoETFs with exposure to Aeglea Biotherapeutics, Inc. : April 28, 2017
finance.yahoo.com - April 28 at 4:01 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Aeglea Bio Therapeutics Inc (AGLE) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 21 at 10:48 PM
finance.yahoo.com logoNew Strong Buy Stocks for April 13th
finance.yahoo.com - April 13 at 3:37 PM
americanbankingnews.com logoAeglea Bio Therapeutics Inc (AGLE) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:33 PM
zacks.com logoNew Strong Buy Stocks for April 12th
www.zacks.com - April 12 at 12:03 PM
bizjournals.com logoAustin biotech startup with $7M more in funding wants to beef up cancer-fighting drugs
www.bizjournals.com - April 10 at 3:22 PM
americanbankingnews.com logoShort Interest in Aeglea Bio Therapeutics Inc (AGLE) Drops By 39.0%
www.americanbankingnews.com - April 8 at 1:20 PM
americanbankingnews.com logoAnalysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Announce ($1.15) Earnings Per Share
www.americanbankingnews.com - April 6 at 8:04 AM
finance.yahoo.com logoEdited Transcript of AGLE earnings conference call or presentation 23-Mar-17 8:30pm GMT
finance.yahoo.com - March 30 at 3:48 PM
finance.yahoo.com logoAeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
finance.yahoo.com - March 29 at 8:32 PM
finance.yahoo.com logoAEGLEA BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - March 29 at 3:29 PM
finance.yahoo.com logoAeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 8:24 PM
biz.yahoo.com logoQ4 2016 Aeglea Bio Therapeutics Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 23 at 11:29 PM
us.rd.yahoo.com logoAeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
us.rd.yahoo.com - March 23 at 11:29 PM
us.rd.yahoo.com logoAeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 23 at 11:29 PM
biz.yahoo.com logoAeglea Bio Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
us.rd.yahoo.com - March 23 at 11:29 PM
finance.yahoo.com logo8:03 am Aeglea BioTherapeutics will present topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Arginase I deficiency at the ACMG Annual Meeting
finance.yahoo.com - March 23 at 3:35 PM
americanbankingnews.com logoAeglea Bio Therapeutics Inc (AGLE) to Release Earnings on Thursday
www.americanbankingnews.com - March 22 at 7:34 AM
finance.yahoo.com logoAeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
finance.yahoo.com - March 17 at 4:05 PM
seekingalpha.com logoAeglea Biotherapeutics: Interesting Early-Stage Enzyme Therapy
seekingalpha.com - March 9 at 3:27 PM
biz.yahoo.com logoAEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 6:31 AM
finance.yahoo.com logoAeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
finance.yahoo.com - February 28 at 8:22 AM
finance.yahoo.com logoAeglea Biotherapeutics (AGLE) Looks Good: Stock Jumps 7%
finance.yahoo.com - February 23 at 3:24 PM
streetinsider.com logoAeglea BioTherapeutics (AGLE) Appoints Suzanne Bruhn to Board of Directors
www.streetinsider.com - February 18 at 9:30 AM
finance.yahoo.com logoAeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM
finance.yahoo.com logoAeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM
finance.yahoo.com logoAeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM
biz.yahoo.com logoAEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 8:27 PM
biz.yahoo.com logoAEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 8:27 PM

Social

Chart

Aeglea BioTherapeutics (AGLE) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff